SEC Filing Summary: Hemispherx Biopharma, Inc. (10-Q)
Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended March 31, 2009. Hemispherx Biopharma, Inc. is a specialty pharmaceutical company focused on immune system-enhancing technologies. The company's primary strategic focus is the clinical development and regulatory approval of Ampligen® (poly I:C12U) for Chronic Fatigue Syndrome (CFS) and as a vaccine adjuvant. Its only FDA-approved product, Alferon N Injection® (for genital warts), has had commercial sales suspended since April 2008 due to inventory expiration.
Key Financial Metrics
| Metric (in thousands) | Q1 2009 | Q1 2008 |
|---|---|---|
| Total Revenues | $29 | $208 |
| Net Loss | $(3,087) | $(3,165) |
| Loss Per Share (Basic/Diluted) | $(0.04) | $(0.04) |
| Cash & Cash Equivalents (End of Period) | $3,621 | $9,644 |
| Short-Term Investments | $1,920 | $0 |
| Total Liquidity (Cash + ST Inv) | $5,541 | $9,644 |
| Accumulated Deficit | $(200,496) | $(197,409) |
| Net Cash Used in Operating Activities | $(1,424) | $(2,806) |
Note: The filing text does not provide explicit gross margin or operating margin percentages; however, the company reported zero product sales revenue for Q1 2009.
Material Changes vs. Prior Period
- Revenue Decline: Total revenues dropped 86% to $29,000. This was driven by the complete cessation of Alferon N Injection sales ($173,000 in Q1 2008 vs. $0 in Q1 2009) due to expired inventory. Remaining revenue came solely from Ampligen cost-recovery clinical programs.
- Expense Reductions: General and Administrative (G&A) expenses decreased by $731,000 (39%) due to reduced legal fees, accounting costs, and stock compensation. Production costs decreased by 51% due to the lack of commercial sales.
- R&D Increase: Research and Development expenses increased by $288,000 (22%). This included a $100,000 write-off of 21 patents deemed no longer valuable and $388,000 in non-cash labor expenses from the Employee Wage Reduction Program.
- Financing Costs: The company incurred $241,000 in non-cash financing costs related to a Standby Financing Agreement, a new expense not present in the prior year.
- Liquidity: Cash and short-term investments decreased by approximately $4.1 million compared to the prior year quarter, reflecting operating losses and investment purchases.
Outlook, Management Commentary, and Risks
Regulatory Status: The FDA accepted the New Drug Application (NDA) for Ampligen for CFS in July 2008. The Prescription Drug User Fee Act (PDUFA) decision date was extended from February 25, 2009, to May 25, 2009. The company addressed FDA Form 483 observations regarding method validations at its New Brunswick facility.
Liquidity and Financing:
- The company implemented an Employee Wage or Hours Reduction Program effective January 1, 2009, where employees receive "Incentive Rights" (convertible to stock) in lieu of cash wages.
- Proceeds from a Common Stock Purchase Agreement with Fusion Capital Fund II, LLC raised $869,000 in Q1 2009. However, access to this facility is restricted if the stock price averages below $0.40 for three trading days.
- A Standby Financing Agreement was entered into in February 2009, allowing for up to $1,000,000 in loans from individuals if other financing fails.
- Subsequent Event: On May 10, 2009, the company entered into agreements to sell approximately $15 million in securities (common stock and warrants) to institutional investors, expected to close shortly after the filing date.
Risks and Contingencies:
- Product Liability: The company suspended product liability insurance for Ampligen and Alferon in November 2008 to conserve cash, relying on indemnification from third parties for overseas sales.
- Manufacturing: Production of Alferon N Injection is on hold until mid-2009 pending funding; commercial availability may not resume until 2010.
- Legal: A lawsuit by Lovells LP seeking ~£151,000 in legal fees is ongoing; a loss contingency has been recorded.
Investor Verification Checklist
- May 25, 2009 FDA Decision: Verify the outcome of the Ampligen NDA review for Chronic Fatigue Syndrome.
- $15 Million Placement Closing: Confirm the closing of the May 2009 securities offering with institutional investors and the actual proceeds received.
- Stock Price Thresholds: Monitor the stock price relative to the $0.40 threshold required to access the Fusion Capital standby financing.
- Product Liability Exposure: Assess the risk implications of operating without product liability insurance pending regulatory approval.
- Alferon Production Restart: Verify if funding was secured to resume Alferon N Injection production in mid-2009 as planned.